苯巴比妥与扑米酮临床显著药物相互作用系统综述
该系统综述检索至2026年1月的文献,评估苯巴比妥与抗凝药、抗菌药及免疫抑制剂等的药物相互作用。共纳入50项研究,86%显示苯巴比妥影响结局,诱导起效6小时至30天,消退2至8周。
要点
- 苯巴比妥诱导CYP450可导致临床显著药物相互作用
- 诱导起效时间6小时至30天,消退需2至8周
- 多数研究通过治疗药物监测发现相互作用影响结局
核心结论
- 苯巴比妥可导致多类药物的临床显著药物相互作用。
研究设计与样本
- 系统综述检索至2026年1月,纳入50项成人及儿科研究。
主要发现
- 86%的纳入研究显示苯巴比妥对结局有影响,常与治疗药物监测相关。
- 8项研究评估诱导消退,范围为2至8周。
- 有限数据提示苯巴比妥剂量与CYP诱导程度存在剂量反应关系。
临床怎么用
- 使用苯巴比妥时应警惕其CYP450诱导作用,必要时通过治疗药物监测管理相互作用。
- 关注诱导起效与消退时间窗,以调整合用药物的剂量或监测方案。
局限性
- 关于苯巴比妥剂量与CYP诱导程度的剂量反应关系数据有限。
- 未来需聚焦临床结局及单次高剂量苯巴比妥对药物相互作用影响的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Phenobarbital (PB) is historically used for management of seizure disorders but more recently has emerged as a prominent option for the management of alcohol withdrawal syndrome given data suggesting its benefit over benzodiazepines. An important consideration of PB therapy is its induction of cytochrome-P 450 enzymes (CYP450), which may lead to underrecognized drug-drug interactions (DDIs). Knowledge of these PB DDIs, including their onset and offset, is important to better elucidate how to manage these DDIs. To identify published literature evaluating the relevance of DDIs between PB and selected medications, a systematic review was performed including literature published through January 2026, focused on the administration of both PB and a list of medications based on tertiary medication database review as well as clinical relevance, including anticoagulants, antimicrobials, and immunosuppressants. Included articles had to identify outcomes of interest, which were focused on laboratory, pharmacokinetic, and clinical outcomes, and had to be in humans. Data extraction included the onset and offset of PB DDIs and potential PB dose-response and magnitude of induction of target medication. A total of 3271 articles were identified, with 50 studies meeting inclusion criteria, which included both adult and pediatric populations. Thirteen studies evaluated onset of PB induction, which ranged from 6 h to 30 days. Eight studies evaluated offset of PB induction, which ranged from 2 to 8 weeks. Limited data demonstrated a PB dose-response relationship in terms of magnitude of CYP induction. We found that 86% of the included studies demonstrated an impact by PB on outcomes, which were often related to therapeutic drug monitoring. Data suggest that PB does lead to clinically significant DDIs in multiple classes of medications. Future areas of research include focused evaluations on clinical outcomes, as well as studies specifically evaluating single high-dose PB and impact on DDI outcomes.
引用
- Ghattas K, Liu JT, Elsamadisi P, et al. A Systematic Review of Clinically Significant Drug-Drug Interactions With Phenobarbital and Primidone. Pharmacotherapy. 2026. PMID: 41833537. doi:10.1002/phar.70133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。